Coherus BioSciences Dirección
Dirección controles de criterios 3/4
El CEO de Coherus BioSciences es Denny Lanfear , nombrado en Sep 2010, tiene una permanencia de 14.17 años. compensación anual total es $5.90M, compuesta por 16.7% salario y 83.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.99% de las acciones de la empresa, por valor de $937.64K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.3 años, respectivamente.
Información clave
Denny Lanfear
Chief Executive Officer (CEO)
US$5.9m
Compensación total
| Porcentaje del salario del CEO | 16.7% |
| Permanencia del CEO | 14.2yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$450k |
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$983k | -US$238m |
| Sep 30 2023 | n/a | n/a | -US$217m |
| Jun 30 2023 | n/a | n/a | -US$264m |
| Mar 31 2023 | n/a | n/a | -US$271m |
| Dec 31 2022 | US$7m | US$945k | -US$292m |
| Sep 30 2022 | n/a | n/a | -US$279m |
| Jun 30 2022 | n/a | n/a | -US$230m |
| Mar 31 2022 | n/a | n/a | -US$210m |
| Dec 31 2021 | US$9m | US$885k | -US$287m |
| Sep 30 2021 | n/a | n/a | -US$232m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$7m | US$857k | US$132m |
| Sep 30 2020 | n/a | n/a | US$162m |
| Jun 30 2020 | n/a | n/a | US$181m |
| Mar 31 2020 | n/a | n/a | US$145m |
| Dec 31 2019 | US$5m | US$751k | US$90m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$4m | US$702k | -US$209m |
| Sep 30 2018 | n/a | n/a | -US$196m |
| Jun 30 2018 | n/a | n/a | -US$196m |
| Mar 31 2018 | n/a | n/a | -US$208m |
| Dec 31 2017 | US$3m | US$656k | -US$238m |
Compensación vs. Mercado: La compensación total de Denny($USD5.90M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD652.28K).
Compensación vs. Ingresos: La compensación de Denny ha sido consistente con los resultados de la empresa en el último año.
CEO
Denny Lanfear (69 yo)
14.2yrs
Permanencia
US$5,897,924
Compensación
Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 14.2yrs | US$5.90m | 0.99% $ 937.6k | |
| Former Interim CFO | 2.2yrs | US$1.07m | 0.023% $ 21.7k | |
| Chief Commercial Officer | 3.8yrs | US$1.93m | 0.071% $ 66.8k | |
| Chief Technical Officer | 2.8yrs | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Executive Vice President of General Counsel | less than a year | sin datos | sin datos | |
| Vice President of Communications | no data | sin datos | sin datos | |
| Executive Vice President of Corporate Development | 1.8yrs | sin datos | sin datos | |
| Chief Human Resources Officer | no data | sin datos | sin datos | |
| Senior Vice President of Commercial Analytics & Trade | no data | sin datos | sin datos | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Chief Medical Officer | 2.7yrs | sin datos | sin datos |
2.8yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CHRS se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 14.2yrs | US$5.90m | 0.99% $ 937.6k | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Lead Independent Director | 12.8yrs | US$228.69k | 0.087% $ 82.1k | |
| Independent Director | 3.8yrs | US$198.69k | 0.0076% $ 7.2k | |
| Independent Director | 10.5yrs | US$65.00k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$186.19k | 0% $ 0 | |
| Member of Strategic Advisory Board | 1.2yrs | sin datos | sin datos | |
| Independent Director | 2.5yrs | US$188.69k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$183.69k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$193.69k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos |
3.3yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de CHRS se considera experimentada (3.3 años de antigüedad promedio).